Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs top healthcare stocks. On March 3 at the 47th Annual Raymond James Institutional Investor Conference, CEO Marc Casper outlined a strong strategic outlook for Thermo Fisher Scientific Inc. (NYSE:TMO) and future growth prospects.
The executive reiterated that the company is well-positioned to achieve 3% to 4% growth in 2026, given its robust market position. The company delivered 2% organic growth last year and is targeting a long‑term expansion rate of 5% to 6%. The robust growth will come as the company increasingly leverages AI to enhance operations and capitalize on market opportunities. In addition, there is increased focus on capital deployments towards mergers and acquisitions to strengthen the core business.
Thermo Fisher Scientific is in the process of completing the Olink acquisition, which is expected to enhance its endpoint solution capabilities. It’s also targeting other acquisitions with the aim of delivering high value to customers and strong returns.
Thermo Fisher Scientific Inc. (NYSE:TMO) is the world leader in serving science, providing over 2 million products and services for pharmaceutical development, biotechnology research, clinical diagnostics, and laboratory management. It supplies instruments, consumables, and software to accelerate research, enhance diagnostics, and manufacture medicines.
While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.